>>Andrew Jacobs and Matt Richtel, The New York Times
Published: 2019-04-09 22:26:24 BdST
But when similar outbreaks take place at hospitals on US soil, the CDC makes no such public announcement. That is because under its agreement with states, the CDC is barred from publicly identifying hospitals that are battling to contain the spread of dangerous pathogens.
The rise of a deadly drug-resistant fungus called Candida auris, a focus of a New York Times report last weekend, has raised fresh questions about the secrecy enveloping infectious outbreaks at American medical institutions.
Patient advocates say hospitals and health authorities are often slow to alert the public about drug-resistant germs, potentially endangering patients.
“They might not get up and go to another hospital, but patients and their families have the right to know when they are at a hospital where an outbreak is occurring,” said Lisa McGiffert of the Patient Safety Action Network. “That said, if you’re going to have hip replacement surgery, you may chose to go elsewhere.”
Kevin Kavanagh, board chairman of the advocacy group Health Watch USA, contrasted the CDC’s handling of the infections in Tijuana with a 2016 outbreak of a different drug-resistant pathogen, known as carbapenem-resistant Enterobacteriaceae, or CRE, at a rural hospital in Kentucky. It was not until early 2018 that the CDC issued a report on that outbreak — and even then, the agency did not name the hospital where it occurred.
CRE sometimes kills up to half of people infected. No deaths were reported in the Kentucky outbreak, but at least two dozen patients at the hospital were colonised with the bug, meaning they were not sick but could have spread it to others.
The report identified a cleaning cart as a possible source for the spread of the pathogen, which had travelled between the hospital’s emergency room and its surgical ward.
The CDC declined to comment, but in the past officials have said their approach to confidentiality is necessary to encourage the cooperation of hospitals and nursing homes, which might otherwise seek to conceal infectious outbreaks.
Those pushing for increased transparency say they are up against powerful medical institutions eager to protect their reputations, as well as state health officials who also shield hospitals from public scrutiny.
In California, state Sen. Jerry Hill, D-San Mateo, a longtime advocate for tougher restrictions on antibiotic use, found himself stymied in his effort to improve the industry’s reporting on drug-resistant infections. A bill he introduced in the state Legislature would have required hospitals to regularly disclose resistant infections and deaths. In 2017 the Senate passed the bill, 40-0, but it had powerful opponents, including the California Hospital Association, the Infectious Disease Association of California and the state’s Department of Health. The bill then moved to the Assembly, where last year it stalled for lack of support.
Federal legislation that seeks to combat antibiotic resistance through stronger surveillance and better data collection has also stalled. The bill, introduced by Sen. Sherrod Brown, D-Ohio, has yet to emerge from a Senate health committee. “We’ve ignored this looming crisis by doing nothing,” Brown said.
Hospital administrators and public health officials say the emphasis on greater transparency is misguided. Dr Tina Tan, the top epidemiologist at the New Jersey Department of Health, said that alerting the public about hospitals where cases of Candida auris have been reported would not be useful because most people were at low risk for exposure and public disclosure could scare people away from seeking medical care.
“That could pose greater health risks than that of the organism itself,” she said.
Nancy Foster, vice president for quality and patient safety at the American Hospital Association, agreed, saying that publicly identifying health care facilities as the source of an infectious outbreak was an imperfect science.
“That’s a lot of information to throw at people,” she said, “and many hospitals are big places, so if an outbreak occurs in a small unit, a patient coming to an ambulatory surgical centre might not be at risk.”
Still, hospitals and local health officials sometimes hide outbreaks even when disclosure could save lives. Between 2012 and 2014, more than three dozen people at a Seattle hospital were infected with a drug-resistant organism they got from a contaminated medical scope. Eighteen of them died, but the hospital, Virginia Mason Medical Center, did not disclose the outbreak, saying at the time that it did not see the need to do so.
Art Caplan, a bioethicist at New York University School of Medicine, said the issue of full disclosure can be tricky, especially when large hospitals that see huge numbers of seriously ill patients are compared with smaller institutions. “If you’re a hospital of last resort, you’re going to see repeat customers with tough infections, many of them drug resistant,” he said.
Still, he thought there was a greater value in promoting transparency. Public awareness about the lives lost to drug resistant infections, he said, could pressure hospitals to change the way they deal with infection control.
“Who’s speaking up for the baby that got the flu from a hospital worker or for the patient who got MRSA from a bedrail?” he asked, referring to a potentially deadly bacterial infection. “The idea isn’t to embarrass or humiliate anyone, but if we don’t draw more attention to infectious disease outbreaks, nothing is going to change.”
© 2019 New York Times News Service